Certagen GmbH

K764 Hypertrophic Cardio Myopathy 2 (HCM2)


Mutations that are described and validated in one breed can also occur in other breeds. Often these are not published in scientific articles. The occurrence of these mutations in other breeds is determined by the laboratories who perform the tests.

Hypertrophic Cardiomyopathy (HCM) is known in virtually all animal species, including humans. HCM is the most common cause for heart failure in young adults, both humans and animal species. The heart failure is caused by a thickening of the heart muscle, which ultimately results in a loss of function of the heart. In several cat population the clinical risks have been associated with genetic mutations.

It should be noted that in humans with the same disease, there are many different genetic mutations which can cause this disease. Presumably, the situation is similar in cats. In the statistics currently available, approximately half of the Maine Coon cats, which have been diagnosed with HCM by echocardiography or necropsy have the HCM mutation. Obviously, the remaining half have HCM from other causes, probably other mutations. This means that the absence of a mutation in a cat does not mean that it will never develop HCM. Additional mutations will be identified that may be tested for as well. Cats that are positive for the test will not necessarily develop significant heart disease and die from the disease. Some cats will develop a very mild form of the disease and will live quite comfortably, and some might even never develop any signs of the disease. It is not known at this time what makes one cat with the mutation develop HCM early, while another cat develops a much milder and later form, or no signs at all of any heart disease.

In humans, at least 10 mutations have been described, all resulting in HCM. In cats the first mutations have been found, but certainly more mutations in many breeds will be found in future research.

Test specific information

This mutation for HCM2 is a genetic variant identified as A74T of the MYBPC3 gene.

Several tests are available in different breeds. For the different mutations, clinical studies linking a mutation to HCM are not always available. It is up to the owner to decide which test to perform.

Based on a recent inventory at other laboratories, we have learned that the test for HCM2 is not offered internationally. Consequently, we have contacted researchers in the USA. Based on our current information, we have decided to remove the HCM2 test from the Combination Package for Hereditary Diseases. For the moment, the HCM2 test remains available as a separate test.


The disease may show itself on different ages, in which it cannot be estimated when the first symptoms may show themselves. Differences may exist between littermates, and between breeds.

Turnaround time

The Turnaround Time (TAT) depends on various factors, such as the shipment time of your sample to the test location, the test method(s) and whether the tests are performed completely or partially by a Partner Lab or Patent owner.

The TAT of tests performed at our facilities is normally 10 working days after receipt of the sample at the testing laboratory (VHL, VHP or Certagen). For tests performed by a Partner Laboratory (so-called "partner lab test") or patent owner, the TAT is at least 20 working days after receipt of your sample. Because the shipment time to our Partner Labs or patent owner may vary due to factors we cannot influence, the mentioned 20 working days are therefore an estimate.

Sometimes it is necessary to re-run your sample. We call this a retest. In that case, the TAT will of course be extended.

Location of disease or trait

This disease leads to a loss of heart function.

Breed dependence

This DNA test is available for the following breeds: British Longhair, Devon Rex, Maine Coon, Norwegian Forest, Ragdoll, Sacred birman. Additional information is available in the Frequently Asked Questions (FAQ).

Sample type

For this DNA test we accept the following materials: Blood EDTA, Blood Heparin, Tissue, Swab. Please contact Dr. Van Haeringen Laboratorium if you wish to submit other material as listed.


If the result of a DNA test indicates that the animal is not the carrier of a mutation, this is not a guarantee that this animal will never develop HCM. The animal may also be a carrier of a gene that is not yet known and that has accordingly not been tested. If the results of a DNA test indicate that the animal is a carrier of or affected by a mutation, this is normally the basis for the assumption that the animal will develop HCM. Accordingly, there is a possibility that this mutation will be passed on to its offspring.


This genetic factor is inherited in an autosomal, dominant, mode. This means, that the individual can be free of the mutation (homozygote normal), affected (homozygous affected) or carrier (heterozygous affected). Both carriers and affected individuals will show symptoms of the mutation.

Severity of Disease


Code K764

Hypertrophic Cardio Myopathy 2 (HCM2)

€ 50,10 (Incl. 19% VAT)
€ 42,10 (Excl. VAT)